Skip to main content
Terug
CPRX logo

Catalyst Pharmaceuticals, Inc.

Datakwaliteit: 100%
CPRX
NASDAQ Healthcare Biotechnology
€ 23,32
▲ € 0,53 (2,33%)
Marktkapitalisatie: 2,87B
Dagbereik
€ 23,06 € 23,70
52-Weeksbereik
€ 19,05 € 26,58
Volume
1.527.081
50D / 200D Gem.
€ 23,91 / € 22,27
Vorige Slotkoers
€ 22,79

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 13,4 0,4
P/B 3,0 2,9
ROE % 25,5 3,7
Net Margin % 36,4 3,9
Rev Growth 5Y % 43,0 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 33,00 +41.5%
Forward K/W
12,6
Forward WPA
€ 1,85
WPA Groei (sch.)
+0,0%
Omzet Sch.
630 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 2,70
€ 2,57 – € 2,78
 890 M 1
FY2029 € 2,50
€ 2,38 – € 2,57
 840 M 1
FY2028 € 2,24
€ 1,89 – € 2,58
 770 M 2

Belangrijkste Punten

Revenue grew 43,00% annually over 5 years — strong growth
Earnings grew 30,78% over the past year
ROE of 25,49% indicates high profitability
Net margin of 36,39% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 208,61M in free cash flow

Groei

Revenue Growth (5Y)
43,00%
Revenue (1Y)19,78%
Earnings (1Y)30,78%
FCF Growth (3Y)83,64%

Kwaliteit

Return on Equity
25,49%
ROIC20,20%
Net Margin36,39%
Op. Margin43,77%

Veiligheid

Debt / Equity
0,00
Current Ratio6,08
Interest Coverage0,00

Waardering

P/E Ratio
13,37
P/B Ratio3,00
EV/EBITDA8,38
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19,78% Revenue Growth (3Y) 21,62%
Earnings Growth (1Y) 30,78% Earnings Growth (3Y) 73,24%
Revenue Growth (5Y) 43,00% Earnings Growth (5Y) 52,64%
Profitability
Revenue (TTM) 588,99M Net Income (TTM) 214,33M
ROE 25,49% ROA 19,36%
Gross Margin 85,19% Operating Margin 43,77%
Net Margin 36,39% Free Cash Flow (TTM) 208,61M
ROIC 20,20% FCF Growth (3Y) 83,64%
Safety
Debt / Equity 0,00 Current Ratio 6,08
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 13,37 P/B Ratio 3,00
P/S Ratio 4,87 PEG Ratio 0,50
EV/EBITDA 8,38 Dividend Yield 0,00%
Market Cap 2,87B Enterprise Value 2,16B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 588,99M 491,73M 398,20M 214,20M 140,83M
Net Income 214,33M 163,89M 71,41M 83,08M 39,48M
EPS (Diluted) 1,68 1,31 0,63 0,75 0,37
Gross Profit 501,74M 422,89M 346,24M 179,81M 118,95M
Operating Income 257,78M 195,12M 86,81M 101,84M 52,39M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,11B 851,41M 470,11M 375,63M 237,79M
Total Liabilities 152,54M 123,78M 82,23M 75,21M 30,96M
Shareholders' Equity 954,27M 727,63M 387,88M 300,42M 206,83M
Total Debt 2,79M 3,19M 3,56M 3,89M 4,20M
Cash & Equivalents 709,17M 517,55M 137,64M 298,40M 171,45M
Current Assets 894,03M 623,61M 219,33M 320,81M 210,11M
Current Liabilities 147,15M 120,68M 76,06M 57,59M 27,06M

Strategiescores

This stock passed the criteria for 7 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#969 of 1024
19
Custom Capital Light Compounder
#147 of 213
32
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#88 of 326
61
Growth Growth Investing (Philip Fisher)
#112 of 154
42
Value Value Investing (Warren Buffett)
#63 of 195
49
Custom Balanced Risk
#86 of 148
44
Custom Lower Risk
#77 of 136
43

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026